TME/NIR Dual‐Responsive Zinc‐Based Targeted Nanoagonist for Multimodal Amplification of STING‐Mediated Cancer Immunotherapy
Advanced Science · 2026-09 · 13 (49)
DOI: 10.1002/advs.202523182 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 09.06.2026. Verfasst von Kepeng Hu und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Colorectal Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China. Hauptthemen laut MEDLINE: Immunotherapy, Tumor Microenvironment, Membrane Proteins, Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Department of Science and Technology of Zhejiang Province, China Postdoctoral Science Foundation.
Abstract (Originalsprache)
The precise activation of the cGAS‐STING pathway for effective tumor immunotherapy remains a significant challenge due to the complexity of immune responses and tumor microenvironment (TME) limitations. Here, a multifunctional nanoagonist, cRGD‐PDA/ZIF8@ICG/TPT (cDZ@IP), was developed to realize nano‐metabolite–driven multimodal synergistic activation of the STING pathway and enhanced immune recognition. The agonist combines cRGD peptide‐targeted polydopamine‐coated zeolitic imidazolate framework‐8 with the photosensitizer indocyanine green and the chemotherapeutic drug topotecan. Upon near‐infrared laser irradiation, cDZ@IP degrades within the TME, generating high levels of reactive oxygen species, inducing mitochondrial stress, and releasing endogenous mitochondrial DNA. Additionally, topotecan enhances DNA damage accumulation by inhibiting nuclear DNA repair. Zn 2 + released from the agonist further amplifies cGAS‐STING pathway activation, thereby ensuring a robust immune response. The mild photothermal therapy‐induced immunogenic cell death promotes the initiation of antitumor immunity, while also enhancing the effectiveness of immune checkpoint blockade. In vivo studies show that cDZ@IP significantly inhibits primary and distant tumor growth and prevents lung metastasis, providing a promising strategy for STING pathway‐targeted cancer immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Colorectal Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
- Zhejiang Key Laboratory of Biological Treatment, Hangzhou, Zhejiang, China.
- Key Laboratory of Integrated Traditional Chinese and Western Medicine Research on Anorectal Diseases of Zhejiang Province, Hangzhou, Zhejiang, China.
- School of Basic Medical Sciences and Forensic Medicine, Hangzhou Medical College, Hangzhou, Zhejiang, China.
- School of Materials Science and Engineering, State Key Laboratory of Silicon and Advanced Semiconductor Materials, Zhejiang University, Hangzhou, Zhejiang, China.
- School of Materials Science and Engineering, Nankai University, Tianjin, China.
ORCID-Profile: Zhangfa Song
Förderung
- National Natural Science Foundation of China
- Department of Science and Technology of Zhejiang Province
- China Postdoctoral Science Foundation
- Natural Science Foundation of Zhejiang Province
Zitieren
APA
Hu, K., Wang, J., Zhang, W., Wu, Z., Chen, J., He, Y., Duan, X., He, Y., Xin, X., Xiang, H., Wang, Y., Wu, C., Yi, Y., Meng, Q., Qiao, Y., Cheng, K., Long, X., & Song, Z. (2026). TME/NIR Dual‐Responsive Zinc‐Based Targeted Nanoagonist for Multimodal Amplification of STING‐Mediated Cancer Immunotherapy. Advanced Science, 13(49). https://doi.org/10.1002/advs.202523182
Vancouver
Hu K, Wang J, Zhang W, Wu Z, Chen J, He Y, et al. TME/NIR Dual‐Responsive Zinc‐Based Targeted Nanoagonist for Multimodal Amplification of STING‐Mediated Cancer Immunotherapy. Advanced Science. 2026;13(49). doi:10.1002/advs.202523182
BibTeX
@article{Hu2026,
author = {Hu, Kepeng and Wang, Jiawei and Zhang, Wei and Wu, Zhixuan and Chen, Jing and He, Yujing and Duan, Xiyue and He, Yaoting and Xin, Xin and Xiang, Haoyi and Wang, Yijing and Wu, Chengwei and Yi, Yang and Meng, Qing and Qiao, Yuqian and Cheng, Kui and Long, Xiaojun and Song, Zhangfa},
title = {TME/NIR Dual‐Responsive Zinc‐Based Targeted Nanoagonist for Multimodal Amplification of STING‐Mediated Cancer Immunotherapy},
journal = {Advanced Science},
year = {2026},
volume = {13},
number = {49},
doi = {10.1002/advs.202523182}
}
EUVIMED